BLAINJECTIONINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AHZANTIVE (aflibercept-mrbb) by Formycon is 12. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AHZANTIVE (aflibercept-mrbb) is a fusion protein and soluble decoy receptor that binds vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) to inhibit neovascularization and vascular permeability. It is administered intravitreally to treat retinal diseases including neovascular age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME). This is a biosimilar of aflibercept approved in June 2024 by manufacturer Formycon.
Growth
Early-stage biosimilar with moderate competitive pressure (30/100); team building phase for market penetration in established anti-VEGF ophthalmology market.
Mechanism of Action
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine…
Worked on AHZANTIVE at Formycon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.